Simultaneous Use of Two Retroviral Vectors in Human Gene Marking Trials: Feasibility and Potential Applications
| Autor: | Alexander R. Miller, Michael J. Skotzko, Kristina Rhoades, Arie S. Belldegrun, Cho-Lea Tso, Randhir Kaboo, William H. McBride, Edwin Jacobs, Donald B. Kohn, Robert Moen, James S. Economou |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Genetic Markers
Genetic enhancement Genetic Vectors Molecular Sequence Data Biology Polymerase Chain Reaction Defective virus law.invention Transduction (genetics) Lymphocytes Tumor-Infiltrating Proviruses T-Lymphocyte Subsets Transduction Genetic law Murine leukemia virus Genetics Humans Carcinoma Renal Cell Melanoma Molecular Biology Gene Cells Cultured Polymerase chain reaction Base Sequence Defective Viruses Provirus biology.organism_classification Virology Molecular biology Kidney Neoplasms Real-time polymerase chain reaction Feasibility Studies Molecular Medicine Moloney murine leukemia virus |
| Zdroj: | Human Gene Therapy. 3:619-624 |
| ISSN: | 1557-7422 1043-0342 |
| Popis: | Two Moloney murine leukemia virus (Mo-MLV)-based neoR retroviral vectors--LNL6 and G1Na--were used to transduce various human tumor-infiltrating lymphocytes (TIL) populations. These groups included bulk CD(8+)- and CD(4+)-enriched TIL from human renal cell carcinomas and melanomas. Transduction efficiencies averaged 5% for single 4-hr supernatant infections. Integrated provirus could be detected for up to 4 weeks of in vitro culture. LNL6 provirus could be distinguished from G1Na provirus using specific polymerase chain reaction (PCR) primers. A single neomycin phosphotransferase (neoR) gene copy could be detected in 10(5) TIL. Using quantitative PCR, the relative ratio of LNL6 to G1Na copies in the same sample could be determined even at low copy numbers. These preclinical studies demonstrate the feasibility of using two retroviral marking vectors in human gene therapy efforts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|